CYTK: Analysts See 67% Upside as Stock Drifts Lower
Cytokinetics closed the week at $65.64, barely off a month where the stock has shed nearly 9% and sits roughly 40% below where the analyst consensus thinks it should be trading. The gap between price and conviction is…